California’s Next Governor Faces a Cost Crisis Without a Clear Playbook
Ashley Porter’s diagnosis came with a familiar kind of medical drama: slurred speech, a stroke scare, an MRI, a spinal tap, more blood draws, another MRI, and then a hospital bill that landed with far more force than the diagnosis itself. The roughly $180,000 charge arrived even after insurance covered most of it. For Porter, who was eventually diagnosed with multiple sclerosis, the bill was not an abstraction; it became the bill for staying alive and staying employed in a system where coverage still leaves families exposed.
Her experience sits inside a much larger California problem. Premiums, hospital prices, and drug costs continue to rise faster than inflation, and the state’s governor’s race has offered little in the way of concrete relief. Californians are carrying the highest-premium employer coverage in the country, with the average family premium approaching $28,400 a year, up 24% since 2022. At the same time, more than 40% of adults nationally struggle to afford care, and many want government action because the problem is no longer confined to a few unfortunate bills or a single insurer.
Porter and her husband have insurance through separate employer plans, yet they have spent at least $75,000 a year on medical expenses since her diagnosis. For families with serious chronic illness, the cost burden is not limited to one hospitalization. It accumulates through specialist visits, scans, medications, facility charges, and the long tail of follow-up care that insurance rarely absorbs cleanly. The result is a form of financial toxicity that can be just as destabilizing as the disease itself.
Becerra and Hilton Offer Different Theories, but Few Detailed Mechanisms
Democrat Xavier Becerra, the former U.S. health secretary and California attorney general, has leaned on familiar enforcement tools. He has promised lower drug prices and tougher action against anticompetitive conduct, pointing to his earlier antitrust case against Sutter Health as proof that government can pressure dominant systems. His campaign also calls for restoring federal Medicaid cuts and bringing back enhanced Affordable Care Act tax credits, although both issues rest largely with Congress and the White House rather than the governor’s office.
Republican Steve Hilton has taken a different route. He wants to expand transparency rules, tighten oversight of pharmacy benefit managers, encourage lower-cost insurance products, and use California’s CalRx initiative to promote more generic drugs. He has also proposed personal healthcare accounts of up to $10,000 a year to partially replace Medi-Cal, the state Medicaid program. In a legislature controlled by Democrats, that idea faces a steep climb before it reaches policy form.
Both candidates declined repeated interview requests to discuss their health policy plans in detail. The silence leaves voters with broad themes rather than implementation strategies. For a state that already runs one of the largest healthcare markets in the country, broad themes are not enough to move prices.
Hospital Power, State Caps, and the Limits of Incremental Reform
The underlying economics are brutal. U.S. health expenditures have climbed from $75 billion in 1970 to a projected $5.7 trillion in 2025, and spending is expected to exceed one-fifth of the economy by 2032. Hospitals, doctors, clinics, and prescription drugs account for much of that inflation, while mergers among physician practices, hospital groups, and insurers have made many markets less competitive. When competition weakens, prices tend to rise because patients and employers have fewer alternatives and less leverage at the negotiating table.
California has tried to respond through its Office of Health Care Affordability, which has told most health systems, hospitals, insurers, and large provider groups to keep spending growth to 3.5% this year. Hospital and doctor groups argue the cap is too restrictive, and the California Hospital Association is challenging it in court. Their argument is straightforward: hospitals are expensive to run, and a blunt spending cap could squeeze staffing, services, and access. State officials counter with the opposite reality: hospitals remain the largest driver of commercial spending, and at least 40% of total health spending by commercial plans went to hospitals in 2024.
The Sutter settlement still hangs over this debate. Becerra’s 2018 lawsuit accused the system of using market dominance to push prices up in Northern California, where procedures could cost as much as 30% more than in other regions. The resulting $575 million settlement and restrictions on “all-or-nothing” contracting sent a signal to other systems, but it did not reverse the broader consolidation trend. In pricing terms, one landmark enforcement action can change behavior at the margin, yet it does not automatically reset a market that has kept concentrating power.
One bill can trigger a crisis, but the real damage often arrives in monthly installments.
Families feel that pressure through medical debt and denied breathing room in the rest of their budgets. Kia Frazier-Hill described a hospitalization for her husband at an out-of-network facility that left the family facing $17,507 for a night in the intensive care unit, $427.89 for a flu, covid, and RSV test, and $2.60 for a single Tylenol tablet. Their bronze-tier Covered California plan paid nearly $60,000, yet the remaining $7,500 balance has been in collections for months. Her account is the same story Porter tells from another angle: insurance coverage does not necessarily prevent financial distress when provider prices are high enough.
Small Policy Levers Could Move Faster Than Campaign Promises
Economists and consumer advocates point to narrower reforms that could produce measurable relief faster than sweeping campaign language. California could follow other states that ban certain facility fees, which let hospital-owned clinics bill at hospital-level rates even when care is delivered in outpatient settings. It could also automate prior authorization workflows and set tighter insurer response deadlines, changes that would trim administrative friction and reduce delays in care. Broader bans on anticompetitive contracting and medical debt forgiveness programs would also reach patients more directly than abstract promises about market competition.
The politics are difficult because the healthcare industry spends heavily to shape legislation and regulation. Hospitals, insurers, and physician groups have every incentive to defend the current pricing structure, especially when reimbursement flows are strong and consolidation has already shifted bargaining power. Glenn Melnick, a healthcare economist at the University of Southern California, captured the stakes plainly: the money is so large that lawmakers eventually have to decide whether to keep feeding a system that keeps asking for more.
What California lacks is not evidence of a problem. It lacks a governable consensus on which costs to cut first, who should absorb the losses, and how to force prices down without triggering backlash from the systems that control care delivery. Until a candidate puts forward a detailed financing plan, a regulatory path, and a timeline for implementation, the governor’s race will remain a contest of slogans inside one of the country’s most expensive healthcare markets.